WHO WE ARE
We are dedicated to improving patient outcomes by developing, supplying and delivering molecular diagnostics and therapeutics (theranostics).
The early vision for molecular imaging was to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease. Today, we bring that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology.
With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, we are dedicated to improving patient health.
From the development of the first PET camera in 1973, Dr. Michael Phelps has proven his passion and dedication for the future of PET. His vision began in equipment, building a core PET company comprised of innovation and has lead to pioneering PET imaging. In 2006, the creation of SOFIE launched the aspiration of having a multifaceted approach to expand the reach of PET products for patients with advanced imaging needs. This was further realized in 2017 with the addition of a radiopharmacy network with global distribution capabilities.
Today SOFIE is equally passionate team bringing the vision to life by increasing the adoption and application diversity of theranostics. This is done by providing a suite of meticulously tailored offerings that facilitate the use of and access to the technology. With its full line of imaging and radiochemistry systems, and a premier radiopharmacy network and radiopharmaceutical contract manufacturing organization, SOFIE is dedicated to improving patient health.